Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2012

View Archived Issues

Roche presents novel antibodies targeting human chemokine CXCR5 receptor

Multiple-assay test shows promise to diagnose depression

Phase I trials assess Listeria-based vaccines in patients with cancer

Merck KGaA patents new P70S6K inhibitors

Novel tyrosine-protein kinase JAK inhibitors prepared by Rigel Pharmaceuticals

Novel diacylglycerol O-acyltransferase 1 inhibitors synthesized

Line extension for Zyprexa approved in Japan

UCB begins phase III Cimzia trial

Merck & Co. patents novel beta3-adrenoceptor agonists

Enanta out-licenses EDP-239 development

Washburn Therapeutics patents new wound-healing antibodies

New signaling pathway inhibitors developed in Sweden

New nanopore DNA strand sequencer is the size of a USB stick

NICE recommends earlier use of tocilizumab in RA

NICE confirms guidance on prolonged-release exenatide for type 2 diabetes

Enrollment begins in phase I/II trial of PET imaging agent

BMS gains additional indication approvals for two anticancer drugs

Mechanism and activity of ladarixin sodium explored

FDA advisory committee recommends approval of obesity therapy

Daiichi Sankyo and Terumo enter new vaccine collaboration

Onyx Pharmaceuticals reaches target enrollment in ASPIRE trial

Auxilium grants Actelion exclusive rights to Xiaflex in certain territories

FDA grants first approval for drug-eluting coronary stent use in AMI

NDS for insomnia therapy accepted for review by Health Canada

Collegium Pharmaceutical gives update on COL-003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 28, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Grace Therapeutics hits CRL setback with GTx-104 despite positive trial
BioWorld
Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...